H
Herman Waldmann
Researcher at University of Oxford
Publications - 586
Citations - 51196
Herman Waldmann is an academic researcher from University of Oxford. The author has contributed to research in topics: Transplantation & Antigen. The author has an hindex of 118, co-authored 586 publications receiving 49942 citations. Previous affiliations of Herman Waldmann include Wayne State University & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Reshaping human antibodies for therapy.
TL;DR: A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes.
Journal ArticleDOI
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen,Evy Vandemeulebroucke,Anette-G. Ziegler,Chantal Mathieu,Leonard Kaufman,Geoff Hale,Frans Gorus,Michel Goldman,M Walter,Sophie Candon,Liliane Schandené,Laurent Crenier,Christophe De Block,Jean-Marie Seigneurin,Pieter De Pauw,Denis Pierard,Ilse Weets,Peppy Rebello,Pru Bird,Eleanor Berrie,Mark Frewin,Herman Waldmann,Jean-François Bach,Daniel Pipeleers,Lucienne Chatenoud +24 more
TL;DR: Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes, as suggested by the results of a phase 1 study.
Journal ArticleDOI
"Infectious" transplantation tolerance
Shixin Qin,Stephen P. Cobbold,H Pope,James A. Elliott,Dimitris Kioussis,Joanna D. Davies,Herman Waldmann +6 more
TL;DR: This process of "infectious" tolerance explains why no further immunosuppression was needed to maintain long-term transplantation tolerance in adult mice.
Journal ArticleDOI
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
TL;DR: It is shown here that unmodified monoclonal antibodies can be extremely effective at depleting cells in vivo and can be used for the selective manipulation of different aspects of the immune response.
Journal ArticleDOI
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
Marianne Brüggemann,Gareth T. Williams,C Bindon,Mike Clark,M R Walker,R Jefferis,Herman Waldmann,Michael S. Neuberger +7 more
TL;DR: The results suggest that IgG1 might be the favoured IgG subclass for therapeutic applications in complement-dependent hemolysis and in antibody-dependent cell-mediated cytotoxicity using both human effector and human target cells.